US Broker Ratings

Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a 116% Potential Upside in the Healthcare Sector

Delcath Systems, Inc. (NASDAQ: DCTH) is making waves in the healthcare sector with its avant-garde approach to treating liver cancer. Specializing in the medical devices industry, Delcath focuses on providing..

Akebia Therapeutics (AKBA): Investor Outlook with a Promising 217.65% Potential Upside

Akebia Therapeutics, Inc. (NASDAQ: AKBA) is capturing the attention of investors with its remarkable potential upside of 217.65%, as highlighted by recent analyst ratings. Operating in the healthcare sector, specifically..

GH Research PLC (GHRS) Stock Analysis: A 137% Potential Upside in Biotech

GH Research PLC (NASDAQ: GHRS) is capturing attention in the healthcare sector with its ambitious approach to tackling treatment-resistant depression. As a clinical-stage biopharmaceutical company based in Dublin, Ireland, GH..

Iovance Biotherapeutics, Inc. (IOVA): Investor Outlook Highlights 190.94% Potential Upside

In the dynamic world of biotechnology, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) stands out with a compelling narrative for investors seeking high-risk, high-reward opportunities. The company’s focus on pioneering cell therapies..

Simulations Plus, Inc. (SLP) Stock Analysis: Is a 16.44% Potential Upside Worth the Investment?

Simulations Plus, Inc. (NASDAQ: SLP) is a noteworthy player in the healthcare sector, specifically within the health information services industry. With a market capitalization of $386.37 million, this North Carolina-based..

CorMedix Inc. (CRMD) Stock Analysis: A Promising 55.87% Upside in Biotech

Investors looking for compelling opportunities in the biotechnology sector may find CorMedix Inc. (NASDAQ: CRMD) an intriguing prospect. With a focus on developing therapeutic products for critical health conditions, CorMedix..

RxSight, Inc. (RXST)

⚠️ No article content returned.

..

Xeris Biopharma Holdings, Inc. (XERS): Investor Outlook with a 54.55% Potential Upside

Xeris Biopharma Holdings, Inc. (XERS) is making significant strides in the biotechnology sector, specializing in the development and commercialization of therapies for chronic endocrine and neurological diseases. With a market..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Exploring Key Metrics and 31.40% Revenue Growth

For investors focused on the healthcare sector, particularly in the specialty and generic drug manufacturing industry, Collegium Pharmaceutical, Inc. (NASDAQ: COLL) presents a compelling case. Situated in Stoughton, Massachusetts, this..

Weave Communications (WEAV) Stock Analysis: Exploring a 48.39% Potential Upside

Weave Communications, Inc. (NYSE: WEAV), a key player in the healthcare sector, is making waves with its innovative customer experience and payments software platform tailored for small and medium-sized healthcare..

Nutex Health Inc. (NUTX) Stock Analysis: Exploring a 48.72% Potential Upside with Robust Revenue Growth

For investors seeking opportunities in the healthcare sector, Nutex Health Inc. (NUTX) presents a compelling case with its significant growth potential. Currently priced at $168.1, Nutex Health has experienced dramatic..

Syndax Pharmaceuticals (SNDX) Stock Analysis: A Biotech Gem with 82% Potential Upside

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is capturing investor attention with its promising pipeline in the biotechnology sector, particularly with a potential upside of nearly 82%. As a commercial-stage biopharmaceutical company,..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Exploring a 46.75% Potential Upside in the Biotech Sector

Nurix Therapeutics, Inc. (NRIX), a San Francisco-based clinical-stage biopharmaceutical company, is capturing investor attention with its robust pipeline and strategic partnerships in the biotechnology sector. With a market capitalization of..

Beta Bionics, Inc. (BBNX) Stock Analysis: A Promising Growth Story with 63.10% Revenue Surge

Beta Bionics, Inc. (NASDAQ: BBNX) stands at the forefront of innovation in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $1.37 billion, this U.S.-based..

Oculis Holding AG (OCS) Stock Analysis: Eyeing a 117% Upside in Healthcare Innovation

Oculis Holding AG (NASDAQ: OCS), a burgeoning name in the biotechnology sector, is capturing investor attention with its promising pipeline of ophthalmic treatments and a compelling potential upside of 117.83%...

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Powerhouse with 147% Potential Upside

Enliven Therapeutics, Inc. (NASDAQ: ELVN), a burgeoning player in the biotechnology sector, is capturing attention with its promising pipeline and significant growth potential. Based in Boulder, Colorado, this clinical-stage biopharmaceutical..

STAAR Surgical Company (STAA) Stock Analysis: Navigating Growth in the Medical Instruments Space

STAAR Surgical Company (NASDAQ: STAA) is a prominent player in the healthcare sector, specifically within the medical instruments and supplies industry. Headquartered in Lake Forest, California, the company specializes in..

Cronos Group Inc. (CRON) Stock Analysis: Navigating a Challenging Market with a 6.1% Revenue Growth

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the healthcare sector specializing in cannabinoid products, finds itself at a pivotal moment. With a current market capitalization of $1.05 billion,..

Zymeworks Inc. (ZYME) Stock Analysis: Unveiling a 32% Upside Potential Amidst Robust Revenue Growth

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology firm, is making waves in the healthcare sector with its focus on developing innovative biotherapeutics for cancer and autoimmune diseases. With a market..

Phibro Animal Health Corporation (PAHC) Stock Analysis: Navigating a 13.94% Upside in the Healthcare Sector

Phibro Animal Health Corporation (NASDAQ: PAHC), a stalwart in the healthcare sector, stands out with its diverse portfolio in animal health and mineral nutrition. With a market capitalization of $1.53..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds